It will be of interest to compare NKCC1 and KCC2 expression levels in distinct brain regions in vivo (e.g., Figure 3) as well as in neuronal and glia cells in post-mortem human AD brain during progression of the disease. This evidence concerns the gene SLC12A2 and Alzheimer disease.